博济医药(300404) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was CNY 167,424,382.67, representing a 62.08% increase compared to CNY 103,299,782.23 in the same period last year[5] - Net profit attributable to shareholders was CNY 16,513,092.18, a 40.67% increase from CNY 11,738,526.83 year-on-year[5] - The net profit after deducting non-recurring gains and losses was CNY 14,493,001.71, showing a significant increase of 103.30% compared to CNY 7,129,018.83 in the previous year[5] - The total comprehensive income for the period was CNY 17,821,249.12, a 50.90% increase from CNY 11,809,923.71 year-on-year[12] - Operating profit for Q1 2024 was ¥16,614,526.52, up 29.0% from ¥12,832,014.00 in Q1 2023[29] - Net profit attributable to the parent company for Q1 2024 was ¥16,513,092.18, representing a 40.0% increase from ¥11,738,526.83 in Q1 2023[29] - Basic and diluted earnings per share for Q1 2024 were both ¥0.0432, compared to ¥0.0319 in Q1 2023, reflecting a growth of 35.5%[30] Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 1,451,050,284.79, up 1.55% from CNY 1,428,927,075.12 at the end of the previous year[5] - Total liabilities increased to ¥467,115,066.85 in Q1 2024, up from ¥448,819,898.21 in Q1 2023, reflecting a rise of 4.3%[29] - The company's total equity reached ¥983,935,217.94 in Q1 2024, up from ¥980,107,176.91 in Q1 2023, indicating a slight increase of 0.3%[29] Cash Flow - The net cash flow from operating activities was -CNY 15,764,811.36, a drastic decline of 54,856.43% compared to -CNY 28,686.02 in the same period last year[14] - The cash outflow from operating activities totaled ¥158,025,773.22 in Q1 2024, compared to ¥114,121,021.81 in Q1 2023, showing an increase of 38.4%[32] - The total cash inflow from operating activities was ¥142,260,961.86, compared to ¥114,092,335.79 in the previous year, marking a growth of 24.7%[32] - The total cash and cash equivalents at the end of Q1 2024 were 217,196,530.25, down from 309,606,804.49 at the end of Q1 2023[33] Investments - The company reported a 1926.94% increase in trading financial assets, reaching CNY 149,512,579.22, primarily due to the purchase of wealth management products[10] - The company’s investment activities resulted in a net cash outflow of -CNY 153,727,515.94, a 689.03% increase in outflow compared to -CNY 19,483,138.77 in the previous year[15] - The total cash inflow from investment activities was 152,916,907.74, up from 116,805,083.45 in the previous year, while cash outflow was 306,644,423.68, compared to 136,288,222.22 in Q1 2023[33] Shareholder Information - The total number of common shareholders at the end of the reporting period is 24,171[17] - The top shareholder, Wang Tingchun, holds 31.07% of shares, totaling 118,674,370 shares, with 89,005,777 shares under lock-up[17] - The company has a repurchase account holding 2,667,000 shares, representing 0.70% of the total share capital as of March 31, 2024[18] - The total number of restricted shares at the end of the period is 106,636,426, down from 111,644,058, with 5,007,632 shares released during the period[19] - The top 10 shareholders include individuals and a private fund, with the largest individual shareholder holding over 31%[17] Research and Development - Research and development expenses for Q1 2024 were ¥11,341,330.66, an increase of 13.6% from ¥9,986,450.82 in the same period last year[29] - The company’s subsidiary received approval for the listing application of the raw material drug "Tadalafil" from the National Medical Products Administration[22] - The company’s subsidiary obtained drug registration certificates for "Tadalafil Tablets" in 5mg and 10mg specifications[22] Business Operations - The company increased its new business contract amount to approximately 398 million yuan, representing a year-on-year growth of about 135%[20] - The company has not disclosed any new product developments or market expansion strategies in the current report[18] - The company plans to implement a restricted stock incentive plan, granting 2.9 million shares at a price of 6.62 yuan per share[24]